Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy ...

The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain ...

Daniel Vitt, CEO, Immunic Therapeutics, discusses how the company is positioning itself to lead in the area of gastrointestinal diseases.

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, talks about where patients are turning for trustworthy health information and some strategies that can ...

The funding, led by existing and new investors, is expected to support Eikon’s efforts to integrate advanced computing, ...

The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

Take degenerative disc disease, for example. When you take a fibroblast cell and you put it into the nucleus of the disc, you ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

Surgifort is the first FDA-approved human milk-based fortifier specifically designed for term infants recovering from ...

Aspargo Labs uses a proprietary technology platform to reformulate oral medication to liquid doses. CEO and chairman Michael ...

Vaxitek HVT+IBD+H5 integrates COBRA technology to address the ongoing viral evolution challenges of avian influenza, as well ...

Daniel Vitt, CEO, Immunic Therapeutics, discusses how the safety and tolerabilities results from Phase I trials for IMU-856 influences further studies for gastrointestinal diseases moving forward.